Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: ikenaoncology.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2024 | $8.00 → $2.00 | Outperform → Neutral | Wedbush |
| 9/22/2023 | $11.00 | Outperform | Wedbush |
| 5/4/2023 | $18.00 | Buy | H.C. Wainwright |
| 12/23/2021 | $25.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | $30.00 → $27.00 | Outperform | Credit Suisse |